- Home
- PPCB vs GCTK Comparison
PPCB vs GCTK Comparison
Compare PPCB & GCTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PPCB | GCTK |
|---|---|---|
| Founded | 2007 | 2001 |
| Country | Australia | United States |
| Employees | 2 | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 2.5M |
| IPO Year | 2011 | 2011 |
Fundamental Metrics
Financial Performance| Metric | PPCB | GCTK |
|---|---|---|
| Price | $1.22 | $0.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 137.1K | ★ 17.6M |
| Earning Date | 05-16-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.65 |
| Revenue | N/A | ★ $589,462.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.14 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.06 | $0.25 |
| 52 Week High | $9.36 | $14.14 |
Technical Indicators
Market Signals| Indicator | PPCB | GCTK |
|---|---|---|
| Relative Strength Index (RSI) | 46.76 | 46.86 |
| Support Level | $0.15 | $0.28 |
| Resistance Level | $1.26 | $0.68 |
| Average True Range (ATR) | 0.16 | 0.13 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 42.31 | 19.37 |
Price Performance
Historical ComparisonAbout PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
About GCTK GlucoTrack Inc.
GlucoTrack Inc is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is developing its Glucotrack CBGM system to provide continuous glucose monitoring using implantable sensor technology and is advancing the product through clinical studies and regulatory processes.